{/* Section 1: What is Pharmacovigilance */}

Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. It encompasses all activities undertaken to monitor the safety of medicinal products throughout their entire lifecycle—from preclinical development through clinical trials, marketing authorization, and post-marketing surveillance, up to and including product discontinuation.

The regulatory framework governing pharmacovigilance in the European Union is established by Directive 2001/83/EC, Regulation (EU) No 1235/2010, and the comprehensive set of EU Good Pharmacovigilance Practice (GVP) guidelines (Modules I–XVI), which provide detailed guidance on the conduct of pharmacovigilance activities. At the international level, the ICH E2E guideline on Pharmacovigilance Planning provides a framework for the development and implementation of proactive pharmacovigilance plans during both pre-approval and post-approval phases.

Espandiar Pharmaceuticals recognizes pharmacovigilance as a fundamental ethical and legal obligation and a cornerstone of patient safety. Our pharmacovigilance system is designed to ensure that the benefit-risk profile of every Espandiar product is continuously monitored, evaluated, and communicated to regulatory authorities, healthcare professionals, and patients in a timely and transparent manner.

{/* Section 2: Espandiar's PV System */}

Espandiar Pharmaceuticals maintains a comprehensive, fully integrated pharmacovigilance system that complies with the requirements of EU GVP Module II (Pharmacovigilance System Master File) and ICH E2E. The system encompasses all organizational structures, processes, resources, and quality management measures necessary for the effective performance of pharmacovigilance activities.

Qualified Person for Pharmacovigilance (QPPV)

In accordance with Article 28 of Directive 2001/83/EC and EU GVP Module II, Espandiar has appointed a Qualified Person for Pharmacovigilance (QPPV) who is responsible for the establishment and maintenance of the pharmacovigilance system, the preparation and submission of all required regulatory safety reports (including SUSARs, PSURs/PBRERs, and RMP updates), and for ensuring that Espandiar fulfills all of its pharmacovigilance obligations under applicable legislation. The QPPV has the authority and organizational independence to fulfill these responsibilities and reports directly to senior management on all pharmacovigilance matters of significant impact.

Espandiar’s pharmacovigilance system includes: a dedicated safety database compliant with ICH E2B(R3) electronic transmission standards; defined Standard Operating Procedures (SOPs) for all critical pharmacovigilance processes; qualified and trained pharmacovigilance personnel including medical assessors, safety scientists, and drug safety associates; a Pharmacovigilance System Master File (PSMF) maintained in accordance with GVP Module II; and a quality management system that ensures continuous improvement through regular internal audits and management reviews.

{/* Section 3: Reportable Events */}

Espandiar encourages the reporting of all suspected adverse reactions and drug-related events associated with Espandiar products. The following categories of events are considered reportable:

Adverse Drug Reactions (ADRs)

Any noxious and unintended response to a medicinal product, whether or not considered related to the product. This includes all adverse reactions that occur at normal doses used for prophylaxis, diagnosis, or treatment of disease, or for the modification of physiological function. ADRs include both serious and non-serious reactions, as well as expected (listed) and unexpected (unlisted) reactions.

Serious Adverse Drug Reactions (SADRs)

Any adverse reaction that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is an important medical event that may jeopardize the patient or require medical or surgical intervention to prevent one of the outcomes listed above. Serious ADRs are subject to expedited regulatory reporting within mandated timeframes.

Adverse Events (AEs)

Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the product.

Medication Errors

Any unintentional error in the prescribing, dispensing, or administration of a medicinal product while in the control of the healthcare professional, patient, or consumer. This includes errors involving the wrong product, wrong dose, wrong route of administration, wrong patient, wrong timing, or incorrect duration of use. Medication errors are reportable even when no adverse reaction has occurred, as they may indicate systemic issues with product design, labeling, or packaging.

Product Quality Complaints

Any complaint relating to the quality of an Espandiar product, including issues with packaging, labeling, appearance, physical properties (color, odor, consistency), tablet/capsule integrity, contamination, stability, or any other quality attribute that deviates from the registered specifications. Product quality complaints are assessed for potential safety implications and are investigated in coordination with Quality Assurance.

Lack of Efficacy

Reports of therapeutic failure or lack of expected clinical response to an Espandiar product when used as directed. While lack of efficacy alone may not constitute a safety concern, it may indicate issues with product quality, bioavailability, or the need for updated clinical guidance, and is therefore captured and assessed within the pharmacovigilance system.

Abuse, Misuse, and Overdose

Reports of intentional abuse, unintentional misuse (use outside the terms of the marketing authorization), or accidental or intentional overdose of Espandiar products. Such reports are critical for understanding the real-world safety profile of products, particularly those with known abuse potential, and may inform risk minimization measures.

{/* Section 4: Who Should Report */}

Pharmacovigilance is a shared responsibility. Espandiar encourages all individuals and organizations who become aware of a suspected adverse reaction or other reportable event to report it. Reports are welcome from the following groups:

Healthcare Professionals: Physicians, pharmacists, nurses, dentists, midwives, and all other licensed healthcare professionals who prescribe, dispense, or administer Espandiar products and observe or suspect an adverse reaction in their patients. Healthcare professionals are often the primary source of high-quality safety reports and play a critical role in pharmacovigilance.

Patients and Consumers: Individuals who have used an Espandiar product and have experienced an adverse reaction or other drug-related problem. Patient reports are particularly valuable because they provide unique insights into the subjective experience and real-world impact of adverse reactions. No medical knowledge is required to submit a report.

Espandiar Employees: All employees of Espandiar Pharmaceuticals and its affiliates are required to report any adverse event or product quality complaint of which they become aware in the course of their professional activities, including medical representatives, clinical operations staff, quality assurance personnel, regulatory affairs professionals, and customer service staff. Internal reporting obligations are governed by Espandiar’s pharmacovigilance SOPs.

Other Stakeholders: Clinical trial investigators, Contract Research Organizations (CROs), distributors, wholesalers, pharmacovigilance contract service providers, and any other party who becomes aware of a safety concern relating to an Espandiar product.

{/* Section 5: How to Report */}

Espandiar provides multiple channels for the reporting of adverse events and product quality complaints. We encourage reporters to use whichever channel is most convenient. All reports are reviewed by qualified medical professionals and are treated with the strictest confidentiality in accordance with applicable data protection laws, including the GDPR and pharmaceutical-specific data protection provisions.

Email Reporting (Preferred)

Reports can be submitted via email to safety@espandiarPharma.com. Email reports are monitored continuously during business hours and by our on-call safety team outside business hours. Please include as much detail as possible (see Section 6 below) to facilitate the assessment of your report.

Telephone Reporting (24/7)

A 24-hour, 7-day-a-week telephone line is available for urgent safety reports and for reporters who prefer to provide their report verbally. Our trained pharmacovigilance staff will document your report and, if necessary, follow up with you for additional information. Please contact our Pharmacovigilance department to obtain the dedicated 24/7 safety reporting telephone number.

Online Reporting Form

An online adverse event reporting form is available on the Espandiar website. The form guides reporters through the required information fields and allows for the attachment of supporting documents. Reports submitted through the online form are directed immediately to the Pharmacovigilance department for processing.

National Reporting Systems

In addition to reporting directly to Espandiar, healthcare professionals and patients are encouraged to report suspected adverse reactions to their national competent authority through the national spontaneous reporting system. In Germany, reports can be submitted to the Federal Institute for Drugs and Medical Devices (BfArM) or the Paul Ehrlich Institute (PEI, for vaccines and biomedicines). Reports to national authorities are shared with Espandiar through the EudraVigilance database and other regulatory reporting channels.

{/* Section 6: What Information to Include */}

To facilitate the thorough assessment of your report, please provide as much of the following information as possible. Even if some details are unavailable, please submit your report—partial reports are valuable and will be followed up by our pharmacovigilance team to obtain additional information where necessary:

Patient Details: Age or date of birth, sex/gender, weight (if relevant), relevant medical history, and any known allergies or concomitant conditions. Patient identifiers should be provided in a coded or pseudonymized form (e.g., patient initials) to protect patient confidentiality.

Suspect Product(s): The name of the Espandiar product(s) suspected to have caused the reaction, including the product name (brand name or INN), dosage form, strength, batch/lot number (if available), route of administration, dose, and dates of use (start and stop dates, if known).

Description of the Reaction: A detailed description of the adverse event or reaction, including the nature of the event, the body system affected, the date of onset, the duration and severity of the reaction, and whether the reaction has resolved. Please include any relevant clinical investigation results (laboratory values, diagnostic findings) if available.

Timing and Causality: The time interval between the administration of the suspect product and the onset of the reaction. If the product was discontinued and the reaction abated (dechallenge), or if the product was re-administered and the reaction recurred (rechallenge), please provide this information, as it is important for causality assessment.

Outcome: The outcome of the adverse event (e.g., recovered/resolved, recovering/resolving, not recovered/not resolved, fatal, unknown). If the patient died, please provide the date of death and, if known, the cause of death and whether an autopsy was performed.

Concomitant Medications: All other medications (prescription, over-the-counter, herbal remedies, dietary supplements) that the patient was taking at the time of the event, including product names, doses, and dates of use. This information is critical for identifying potential drug-drug interactions.

Reporter Details: Your name, professional qualifications (if applicable), contact information (email address, telephone number, mailing address), and your relationship to the patient (e.g., treating physician, pharmacist, patient, caregiver). Reporter contact information is used solely for follow-up purposes and is treated with strict confidentiality.

{/* Section 7: Regulatory Reporting */}

Espandiar is legally obligated to report certain safety information to regulatory authorities within defined timeframes. Our regulatory reporting obligations are fulfilled by the Qualified Person for Pharmacovigilance (QPPV) and the pharmacovigilance team:

SUSAR Reporting (GVP Module VI, Article 18 of Directive 2001/83/EC): Suspected Unexpected Serious Adverse Reactions (SUSARs) that occur in clinical trials are reported to the relevant competent authorities and ethics committees. For fatal or life-threatening SUSARs, reports are submitted within 7 calendar days of the Marketing Authorization Holder becoming aware of the reaction. For all other SUSARs, reports are submitted within 15 calendar days. SUSARs are reported through the EudraVigilance clinical trial module in ICH E2B(R3) format.

Spontaneous Reporting (GVP Module VI, Article 107 of Directive 2001/83/EC): All valid spontaneous reports of serious adverse reactions are submitted to the EudraVigilance database within 15 calendar days of receipt. Non-serious adverse reactions are reported within 90 calendar days. All follow-up information that materially alters the assessment of a previously submitted report is submitted within 15 calendar days of receipt.

PSURs / PBRERs (GVP Module IX, Article 107c of Directive 2001/83/EC): Periodic Safety Update Reports (PSURs), now largely superseded by Periodic Benefit-Risk Evaluation Reports (PBRERs) in accordance with ICH E2C(R2), are comprehensive evaluations of the benefit-risk balance of a marketed product. PSURs/PBRERs are submitted at defined data lock points according to the EURD list (Union Reporting Date) and include a comprehensive analysis of all safety data collected during the reporting period, including clinical trial data, spontaneous reports, literature, and other sources.

PADERs (GVP Module IX): Periodic Adverse Drug Experience Reports (PADERs) may be required by certain non-EU regulatory authorities, including the U.S. FDA, as a condition of marketing authorization. PADERs are prepared and submitted in accordance with the specific requirements of the relevant authority.

RMP Updates (GVP Module V, Article 22 of Directive 2001/83/EC): The Risk Management Plan (RMP) for each Espandiar product is updated and submitted to regulatory authorities as required, including upon receipt of new safety information that materially changes the benefit-risk balance, following PSUR/PBRER evaluation with a recommendation for RMP revision, or when significant pharmacovigilance or risk minimization activities are initiated or modified.

{/* Section 8: Signal Detection & Management */}

Signal detection and management are critical components of Espandiar’s proactive pharmacovigilance strategy, in compliance with EU GVP Module IX. A “signal” is defined as information that arises from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action.

Proactive Monitoring: Espandiar conducts systematic, ongoing surveillance of its safety database using both qualitative and quantitative methods. Quantitative signal detection includes statistical disproportionality analyses (e.g., Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)) applied to the aggregate safety data at predefined intervals. Qualitative signal assessment involves expert medical review of individual case safety reports (ICSRs) and their cumulative patterns.

Literature Review: Espandiar performs systematic, regular searches of the global medical literature for reports of adverse reactions associated with its products, as required by GVP Module VI. Literature searches are conducted using major biomedical databases (including PubMed, MEDLINE, Embase, and the Cochrane Library) at defined intervals, with targeted additional searches following the identification of a potential signal. All relevant articles are assessed, and valid ICSRs are entered into the safety database and reported in accordance with applicable timelines.

Data Mining: Advanced data mining techniques, including natural language processing (NLP) and machine learning algorithms, are applied to identify emerging safety signals from large volumes of unstructured data, including spontaneous reports, clinical trial narratives, and social media sources where applicable and ethically justified. Signal validation and prioritization are conducted by a multidisciplinary signal management team comprising medical assessors, safety scientists, and epidemiologists.

{/* Section 9: Risk Management Plans */}

In accordance with EU GVP Module V and Article 5 of the 2001/83/EC Directive as amended, Espandiar develops and maintains a Risk Management Plan (RMP) for each of its marketed medicinal products. The RMP is a strategic document that identifies known and potential risks associated with a product, describes the measures to characterize and minimize those risks, and specifies plans for further data collection and pharmacovigilance activities to address remaining uncertainties about the product’s safety profile.

RMP Development: The RMP is developed as part of the marketing authorization application and is updated throughout the product lifecycle in response to new safety data, regulatory requirements, or changes in the benefit-risk assessment. The RMP comprises four main parts: the Safety Specification (identification and characterization of risks), the Pharmacovigilance Plan (routine and additional PV activities), and the Risk Minimization Plan (measures to prevent or reduce risks), together with an overall benefit-risk evaluation.

Routine Pharmacovigilance Activities: These include the standard operations of the pharmacovigilance system, such as the collection and processing of spontaneous reports, literature monitoring, signal detection, and the submission of PSURs/PBRERs. These activities are conducted for all marketed products regardless of the identified risk profile.

Additional Pharmacovigilance Activities: Where routine PV activities are insufficient to characterize a specific risk or to address an identified safety concern, the RMP may specify additional activities such as post-authorization safety studies (PASS), registries, or targeted follow-up programs. These activities are designed to provide additional data to refine the understanding of the product’s safety profile and may be required as a condition of the marketing authorization.

Risk Minimization Measures: Risk minimization measures include both routine measures (Summary of Product Characteristics, Patient Information Leaflet, labeling) and additional measures (educational programs, restricted access programs, pregnancy prevention programs, REMS-style programs where applicable, Dear Healthcare Professional Communications) designed to prevent or reduce the occurrence of adverse reactions. The effectiveness of risk minimization measures is regularly evaluated and the RMP is updated accordingly.

{/* Section 10: Product Recalls */}

In the event that a product quality issue or safety concern necessitates the recall of an Espandiar product from the market, Espandiar will initiate a product recall in accordance with the applicable regulatory requirements of the jurisdiction(s) in which the affected product is marketed. Product recalls are classified by severity (Class I, II, or III) in accordance with the EU Medical Device Regulation classification system and national pharmaceutical legislation, and the recall procedure is executed in coordination with the relevant competent authorities.

Recall Procedure: Upon identification of a quality or safety issue that warrants a recall, the Quality Assurance and Pharmacovigilance departments conduct a rapid risk assessment to determine the scope and severity of the issue. A cross-functional recall team is convened, and a recall strategy is developed, including the identification of affected batches, the determination of the recall classification, and the preparation of all required communications and documentation. The recall is initiated following approval by the QPPV and the Head of Quality Assurance.

Communication: Affected stakeholders, including wholesale distributors, pharmacies, healthcare professionals, and (where necessary) patients, are notified promptly through appropriate communication channels. A Dear Healthcare Professional Communication (DHPC) may be issued for safety-related recalls. All recall communications are reviewed and approved by the QPPV and, where required, by the relevant competent authority before dissemination.

Regulatory Notification: The relevant national competent authorities and, where applicable, the EMA are notified of the recall in accordance with the applicable regulatory timelines. Espandiar cooperates fully with regulatory authorities during the recall process and provides all requested information, including root cause analysis findings, corrective and preventive actions (CAPA), and recall effectiveness checks.

{/* Section 11: Periodic Safety Reports */}

Espandiar prepares and submits Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) in accordance with EU GVP Module IX, ICH E2C(R2), and the EURD list (European Union Reference Dates for PSUR submission). These comprehensive reports provide a critical evaluation of the benefit-risk balance of each Espandiar product based on all available safety data collected during the reporting period.

Submission Schedule: The frequency and data lock points for PSUR/PBRER submission are determined by the EURD list, which is published and maintained by the EMA. Newly authorized products typically require more frequent submissions (e.g., every 6 months) during the initial post-authorization period, with the frequency decreasing to annually and eventually every three years as the product’s safety profile becomes better established. The submission schedule is harmonized across EU Member States through the EURD list to avoid duplicate reporting.

Report Contents: Each PSUR/PBRER includes: a comprehensive summary and critical analysis of all safety data from spontaneous reporting, clinical trials, post-authorization safety studies, literature, and other sources; an evaluation of the benefit-risk balance with a conclusion on whether it remains favorable; a summary of any actions taken or proposed in response to identified safety concerns; an overview of the global marketing authorization status; and any updates to the Risk Management Plan. The report also addresses any evaluation requested by the PRAC (Pharmacovigilance Risk Assessment Committee) in the context of the PSUR single assessment procedure.

{/* Section 12: Important Safety Information */}

This section is reserved for the communication of current important safety information relating to Espandiar products. When new safety information becomes available that requires direct communication to healthcare professionals or patients, Espandiar will publish the relevant safety communications in this section. Such communications may include Dear Healthcare Professional Communications (DHPCs), Urgent Safety Restrictions, product labeling updates, and other safety-related notices.

Current Status

There are currently no outstanding safety communications, DHPCs, or urgent safety restrictions requiring publication on this page. Healthcare professionals and patients are encouraged to check this page regularly for updates, and to report any adverse events through the channels described in Section 5 above.

All healthcare professional communications issued by Espandiar are also made available through the relevant national competent authority channels (e.g., the BfArM website in Germany) and through the EMA’s Direct Healthcare Professional Communications (DHPC) repository. Espandiar ensures that all safety communications are developed in accordance with GVP Module XV and are reviewed and approved by the QPPV before dissemination.

{/* Section 13: Contact Information */}

For all pharmacovigilance-related inquiries, including the reporting of adverse events, product quality complaints, or requests for safety information, please contact us through the following channels:

Pharmacovigilance & Safety Reporting

Email: safety@espandiarPharma.com
Available 24 hours a day, 7 days a week for urgent safety reports.

Medical Information

Email: medicalinfo@espandiarPharma.com
For healthcare professionals seeking product-related medical information, scientific literature, or clinical data.

Ethics & Compliance

Email: ethics@espandiarPharma.com
For confidential reporting of compliance concerns, ethics violations, or potential misconduct. All reports are treated with the strictest confidentiality.

All safety reports are treated with the strictest confidentiality in accordance with applicable data protection laws, including the EU General Data Protection Regulation (GDPR) and pharmaceutical-specific confidentiality provisions. Patient identifiers are pseudonymized in all reports, and personal data is processed only to the extent necessary for pharmacovigilance purposes.